Visual hallucinations and Charles Bonnet syndrome after photodynamic therapy for age related macular degeneration

British Journal of Ophthalmology

Volumn 87, Issue 8, 2003, Pages 977-979

  Cohen, Salomon Y ^a   Bulik, A ^a   Tadayoni, R ^a   Quentel, G ^a  

^a Centre Ophtalmologique d'Imagerie et de Laser   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE;

ADULT; AGE DISTRIBUTION; AGED; ANALYSIS OF VARIANCE; ARTICLE; CHARLES BONNET SYNDROME; DISEASE CLASSIFICATION; FACE; FEMALE; GENDER; GEOMETRY; HUMAN; LIGHT; MAJOR CLINICAL STUDY; MALE; PHOTODYNAMIC THERAPY; PHOTOPSIA; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RISK ASSESSMENT; RISK FACTOR; SCHEFFE TEST; SCORING SYSTEM; STATISTICAL ANALYSIS; STRUCTURED VISUAL HALLUCINATION; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; VISUAL DISORDER; VISUAL HALLUCINATION;

AGED; AGED, 80 AND OVER; FEMALE; HALLUCINATIONS; HUMANS; MACULAR DEGENERATION; MALE; PHOTOCHEMOTHERAPY; PROSPECTIVE STUDIES; RISK FACTORS; SYNDROME; VISUAL ACUITY;

EID: 0043208653     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.87.8.977     Document Type: Article

References (23)

1. Schmidt-Effurth U, Hasan T, Gragoudas E, et al. Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology 1994;101:1953-61.
2. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. One-year results of 2 randomized clinical trials - TAP Report 1. Arch Ophthalmol 1999;117:1329-45.
3. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Two-years results of 2 randomized clinical trials - TAP Report 2. Arch Ophthalmol 2001;119:198-207.
4. Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin In Photodynamic Therapy Report 2. Am J Ophthalmol 2001;131:541-60.
5. Verteporfin in Photodynamic Therapy (VIP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: 1-year results of a randomized clinical trial - VIP Report No. 1. Ophthalmology 2001;108:841-52.
6. Brown GC, Murphy RP. Visual symptoms associated with choroidal neovascularization. Photopsias and the Charles Bonnet syndrome. Arch Ophthalmol 1992;110:1251-56.
7. Cohen SY, Safran AB, Tadayoni R, et al. Visual hallucinations immediately after macular photocoagulation. Am J Ophthalmol 2000;129:815-6.
8. Au Eong K, Fujii GY, Ng EWM, et al. Transcient formed visual hallucinations following macular translocation for subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol 2001;131:664-6.
9. Fernandez A, Lichtshein G, Vieweg WV. The Charles Bonnet syndrome: a review. J Nerv Ment Dis 1997;185:195-200.
10. Berrios GE, Brook P. The Charles Bonnet syndrome and the problem of visual perceptual disorders in the elderly. Age Ageing 1982;11:17-23.
11. Pliskin NH, Kiolbasa TA, Towle VL, et al. Charles Bonnet syndrome: an early marker for dementia? J Am Geriatric Soc 1996;44:1055-61.
12. Teunisse RJ, Cruysberg JRM, Verbeek A, et al. The Charles Bonnet syndrome: a large prospective study in the Netherlands. Br J Psychiatry 1995;166:254-7.
13. Teunisse RJ, Cruysberg JR, Hoefnagels WH, et al. Visual hallucinations in psychologically normal people: Charles Bonnet's syndrome. Lancet 1996;347:794-7.
14. Pfeiffer RF, Bodis-Wollner I. Charles Bonnet syndrome. J Am Geriatric Soc 1996;44:1128-9.
15. Saperstein DA, Rosenfeld PJ, Bressler NM, et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome. One-year results of an uncontrolled, prospective case series. Ophthalmology 2002;109:1499-505.
16. Karacorlu M, Karacorlu S, Ozdemir H, et al. Photodynamic therapy with verteporfin for choroidal neovascularization in patients with angioid streaks. Am J Ophthalmol 2002;134:360-6.
17. Bonnet C. Essai analytique sur les facultés de J'âme. 2nd ed. Vol II. Copenhague: 1769:176-7.
18. De Morsier G. Le syndrome de Charles Bonnet: hallucinations visuelles des vieillards sans déficience mentale. Ann Med Psychol 1967;125:677-702.
19. Fitzgerald RG. Visual phenomenology in recently blind adults. Am J Psychiatry 1971;127:109-15.
20. Crane WG, Fletcher DC, Schuchard RA. Prevalence of photopsias and Charles Bonnet syndrome in a low vision population. Ophthalmol Clin North Am 1994;7:143-9.
21. Siatkowski RM, Zimmer B, Rosenberg PR. The Charles Bonnet syndrome: visual perceptive dysfunction in sensory deprivation. J Clin Neuro-ophthalmol 1990;10:215-8.
22. Cogan DG. Visual hallucinations as release phenomena. Graefes Arch Klin Exp Ophthalmol 1973;188:139-50.
23. Ziskind E, Jones H, Filante W, et al. Observations on mental symptoms in eye patched patients: hypnagogic symptoms in sensory deprivation. Am J Psychiatry 1966;122:893-900.